Form 4: Amneal Pharmaceuticals Executive Vice President Reports Stock Transactions
SEC Form 4 Filing
Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On February 27, 2024, Nikita Shah, Executive Vice President of Amneal Pharmaceuticals, reported transactions involving Class A Common Stock.
- 35,620 shares were acquired due to the vesting of restricted stock units.
- 18,670 shares were withheld to satisfy tax obligations at a price of $5.71 per share.
- Following these transactions, Ms. Shah directly owns 336,922 shares of Class A Common Stock.
- The restricted stock units were granted on February 27, 2020, and vest in four equal annual installments.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transactions have a minor impact on the overall shareholding structure of the company.
Key Dates
| Date | Description |
|---|---|
| 02/27/2020 | Date restricted stock units were granted, vesting in four equal installments beginning one year later. |
| 02/27/2024 | Date of the reported transactions: vesting of restricted stock units and tax withholding. |
| 02/29/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.